Author Correction: Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study
- Resource Type
- article
- Source
- Nature Communications, Vol 15, Iss 1, Pp 1-2 (2024)
- Subject
Science - Language
- English
- ISSN
- 2041-1723